web analytics
16.3 C
Munich
Saturday, May 28, 2022

Sunshine Biopharma, Inc. (NASDAQ: SBFM) Upwards Bound as Biotech Reports 2 of its Newly Designed mRNA Molecules Effectively Destroy Cancer Cells Grown in Culture.

Sunshine Biopharma, Inc. (NASDAQ: SBFM) has been on a volatile rise since the Company successfully closed an $8 million public offering and was up listed to the Nasdaq Capital Market from the OTCQB. It is rare that a sub penny pink sheet stocks lands on the NASDAQ but Sunshine Biopharma has done just that and recently saw an explosive price increase to spike over $9 per share after the Company said that two of its newly designed mRNA molecules, found in pre-clinical trials, effectively destroy cancer cells grown in culture. The cytotoxicity tests were performed on various cancer cells, including multidrug-resistant breast cancer cells, ovarian adenocarcinoma cells, and pancreatic cancer cells. Toxicity studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little or no cytotoxic effects. These new mRNA molecules are readily adaptable for delivery to patients using the mRNA vaccine technology.  

This is big news for the up-and-coming biotech who has been working on developing a treatment for COVID-19 and has completed the synthesis of four potential inhibitors of PLpro. The Company is also currently advancing SBFM-PL4 in collaboration with the University of Georgia, College of Pharmacy. Additionally, Sunshine is developing Adva-27a, an anti-cancer compound. Clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Canada. Recently Sunshine Biopharma entered into a research agreement with the University of Arizona pursuant to which the University will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2. Under the agreement, the University of Arizona granted the Company first option to negotiate for a commercial, royalty-bearing license for all intellectual property invented or authored by University of Arizona personnel under the research project. 

Sunshine Biopharma, Inc. (NASDAQ: SBFM) is a pharmaceutical and nutritional supplement company focusing on the research and development of proprietary drugs. Since inception, the Company’s proprietary drug development activities have focused on the development of a small molecule called Adva-27a for the treatment of aggressive forms of cancer. A Topoisomerase II inhibitor, Adva-27a has been shown to be effective at destroying Multidrug Resistant Cancer cells including Pancreatic Cancer cells, Breast Cancer cells, Small-Cell Lung Cancer cells and Uterine Sarcoma cells (Published in ANTICANCER RESEARCH, Volume 32, Pages 4423-4432, October 2012). Sunshine Biopharma is direct owner of all issued and pending worldwide patents pertaining to Adva-27a including U.S. Patents Number 8,236,935 and 10,272,065. The Company also develops science-based nutritional supplements, and currently sell one nutritional supplement product through its wholly owned Canadian subsidiary, Sunshine Biopharma Canada Inc.  

During the fall of 2020 SBFM completed the synthesis of four different potential inhibitors of Coronavirus protease. These compounds are based on the technology described in the Company’s patent application filed on May 22, 2020. In September 2020, the Company identified a lead Anti-Coronavirus drug candidate (SBFM-PL4). The screening which pinpointed the lead compound was performed at the University of Georgia, College of Pharmacy under the leadership of Dr. Scott D. Pegan, Director of the Center for Drug Discovery and Interim Associate Head of Pharmaceutical and Biomedical Sciences. The Company expanded its collaboration with Dr. Scott Pegan’s group by entering into a research agreement with the University of Georgia to further develop the Company’s Anti-Coronavirus lead compound, SBFM-PL4. The Company also entered into a research agreement with the University of Arizona pursuant to which the University will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2. Under the agreement, the University of Arizona granted us a first option to negotiate for a commercial, royalty-bearing license for all intellectual property invent. 

To Find out the inside Scoop on SBFM Subscribe to Microcapdaily.com Right Now by entering your Email in the box below

SBFM

Last week Sunshine Biopharma said that two of its newly designed mRNA molecules, found in pre-clinical trials, effectively destroy cancer cells grown in culture. The cytotoxicity tests were performed on various cancer cells, including multidrug-resistant breast cancer cells, ovarian adenocarcinoma cells, and pancreatic cancer cells. Toxicity studies using non-transformed (normal) human cells (HMEC cells) showed that these mRNA molecules had little or no cytotoxic effects. These new mRNA molecules are readily adaptable for delivery to patients using the mRNA vaccine technology.  

According to Sunshine Biopharma, the cytotoxic effects of the subject mRNA molecules were tested on different cancer cells including multidrug resistant breast cancer cells (MCF-7/MDR), ovarian adenocarcinoma cells (OVCAR-3), and pancreatic cancer cells (SUIT-2). In contrast to cancer cells, the mRNA molecules had little cytotoxic effects on non-transformed (normal) human cells (HMEC cells). These mRNA molecules are readily adaptable for delivery into patients using the mRNA vaccine technology. 

On April 25 SBFM reported it has filed a provisional patent application in the United States covering the recently communicated mRNA molecules found in pre-clinical trials to be effective at destroying cancer cells grown in culture. The patent application contains composition and utility subject matter pertaining to the structure and sequence of the relevant mRNA molecules.  

https://twitter.com/zander_odom/status/1518707649834934272

For More on SBFM Subscribe Right Now!

Currently trading over $4 per share, SBFM is that rare sub penny pink sheet stock that lands on the NASDAQ and makes it.  The stock ran to over $9 per share last week after the Company said that two of its newly designed mRNA molecules, found in pre-clinical trials, effectively destroy cancer cells grown in culture. This is big news for the up-and-coming biotech who has been working on developing a treatment for COVID-19 for which it has already completed the synthesis of four potential inhibitors of PLpro. Sunshine Biopharma is also currently advancing SBFM-PL4 in collaboration with the University of Georgia and Adva-27 for which clinical trials for Pancreatic Cancer indication are planned to be conducted at McGill University’s Jewish General Hospital in Canada. Recently Sunshine Biopharma entered into a research agreement with the University of Arizona pursuant to which the University will focus on determining the in vivo safety, pharmacokinetics, and dose selection properties of three University of Arizona owned PLpro inhibitors, followed by efficacy testing in mice infected with SARS-CoV-2. Under the agreement, the University of Arizona granted the Company first option to negotiate for a commercial, royalty-bearing license for all intellectual property invented or authored by University of Arizona personnel under the research project. Microcapdaily was reporting on SBFM when the stock was trading just over $0.01.  We will be updating on SBFM when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with SBFM.

Sign Up now for our 100% FREE Penny Stock Newsletter

Disclosure: we hold no position in SBFM either long or short and we have not been compensated for this article.

More articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest article

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.